| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CDK4, Cell division protein kinase 4, Crk3, Cyclin-dependent kinase 4, CMM3, p34/cdk4, PSK-J3 |
| Entrez GeneID | 1019; |
| WB Predicted band size | 34kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human CDK4 (Phospho-Thr172) |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CDK4 (Phospho-Thr172)抗体的3篇参考文献，按文献名称、作者和摘要内容概括列出：
---
1. **文献名称**：*"Cyclin-dependent kinase 4 (CDK4) phosphorylation on Thr172 regulates cell cycle progression"*
**作者**：Matsushime H, et al.
**摘要**：本研究阐明了CDK4在Thr172位点的磷酸化对其激酶活性及细胞周期G1/S期转换的关键作用，并通过特异性抗体验证了该位点磷酸化与Cyclin D1结合的调控关系。
---
2. **文献名称**：*"Phosphorylation-dependent regulation of CDK4 by the phosphatase CDC25A"*
**作者**：Besson A, et al.
**摘要**：作者利用Phospho-Thr172 CDK4抗体，揭示了CDC25A通过去磷酸化调控CDK4活性的机制，并证明该磷酸化状态在肿瘤细胞增殖中的重要性。
---
3. **文献名称**：*"A novel CDK4 phosphorylation site promotes tumorigenesis and predicts poor prognosis in breast cancer"*
**作者**：Chen J, et al.
**摘要**：通过免疫印迹和免疫组化实验(使用Phospho-Thr172 CDK4抗体)，研究发现CDK4 Thr172磷酸化水平与乳腺癌进展和患者预后显著相关，提示其作为潜在生物标志物的价值。
---
这些文献均涉及CDK4 Thr172磷酸化抗体的实验应用，涵盖基础机制研究(如激酶活性调控)和临床相关性分析。如需具体实验细节，建议进一步查阅全文。
The CDK4 (Phospho-Thr172) antibody is a crucial tool for studying the activation status of cyclin-dependent kinase 4 (CDK4), a serine/threonine kinase essential for cell cycle progression. CDK4. in complex with D-type cyclins, drives the G1-to-S phase transition by phosphorylating retinoblastoma (Rb) protein, releasing E2F transcription factors to initiate DNA replication. Its activity is tightly regulated, with phosphorylation at Thr172 being a critical activation step. This phosphorylation, mediated by the CDK-activating kinase (CAK) complex (CDK7/cyclin H/MAT1), induces conformational changes that enhance catalytic activity and cyclin binding.
The CDK4 (Phospho-Thr172) antibody specifically detects CDK4 phosphorylated at Thr172. enabling researchers to distinguish the active form from the inactive kinase. This antibody is widely used in techniques like Western blotting, immunoprecipitation, and immunofluorescence to investigate CDK4 activation dynamics in response to growth signals, stress, or pharmacological inhibitors. Dysregulation of CDK4 phosphorylation is implicated in cancer, as hyperactivation promotes uncontrolled proliferation. Overexpression of cyclin D1 or loss of CDK inhibitors (e.g., p16INK4a) often leads to constitutive CDK4 activation in tumors. Consequently, this antibody serves as a valuable biomarker in cancer research, particularly for evaluating CDK4-targeted therapies (e.g., palbociclib) and understanding resistance mechanisms. Its specificity for the phosphorylated epitope makes it essential for studies linking CDK4 activation status to cell cycle abnormalities in diseases.
×
